AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29246363
Drug: Brain natriuretic
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brain natriuretic peptide (≥100 pg/mL)
Trial: 29246363
Drug: TNF‐α (≥5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α (≥5.6 pg/mL)
Trial: 29246363
Drug: Troponin (≥0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troponin (≥0.01 ng/mL)
Trial: 21149931
Drug: NEUMUNE (5‐androstenediol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEUMUNE (5‐androstenediol injectable suspension) administered intramuscularly at doses of 50, 100, 200 or 400 mg, either as a single injection or once daily for five consecutive days
Trial: 18057405
Drug: Caffeine supplement
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplement
Trial: 16598180
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive system (Adper Prompt L Pop) applied without prior acid etching
Trial: 12112791
Drug: Salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol xinafoate inhalation before sleep
Trial: 11951580
Drug: Hymecromone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hymecromone (300 mg tablets at a dosage of 1,200 mg/day, 2 tablets midday and evening)
Trial: 7908864
Drug: BRL 35135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 35135 (8 mg)
Trial: 2675854
Drug: Salbutamol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (8 mg)
Trial: 7908864
Drug: Nadolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (20 mg)
Trial: 1865159
Drug: Intensified conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified conventional treatment (ICT)
Trial: 2671247
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (RT)
Trial: 30575798
Drug: ω‐3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 supplementation (triglyceride dietary supplements or prescription ethyl esters)
Trial: 30575798
Drug: Endotoxin challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin challenge (low dose intravenous lipopolysaccharide)
Trial: 27939192
Drug: Ultrasound-guided serratus
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided serratus anterior plane block (SAPB) with 30 mL of 0.25% levobupivacaine followed by 5 mL/hour of 0.125% levobupivacaine
Trial: 27939192
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with a lower dose regimen activated before extubation
Trial: 23545279
Drug: nab-paclitaxel (nab-P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel (nab-P) 100 mg/m² weekly + carboplatin (C)
Trial: 23545279
Drug: solvent-based paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: solvent-based paclitaxel (sb-P) 200 mg/m² every 3 weeks + carboplatin (C)
Trial: 10878692
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 180 mg/trandolapril 2 mg (VT)
Trial: 10878692
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg/hydrochlorothiazide 25 mg (CH)
Trial: 22960888
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow mononuclear cell therapy
Trial: 17001575
Drug: Simeticone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeticone (300 mg) administered 20 min before capsule endoscopy
Trial: 10494365
Drug: Dimenhydrinate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate (1 mg x kg‐1)
Trial: 11413698
Drug: Droperidol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (15 micrograms x kg‐1) + Dimenhydrinate (1 mg x kg‐1)
Trial: 8215477
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of mitomycin C combined with PJ-203 (600 +/- 300 mg)
Trial: 8215477
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of mitomycin C alone (control)
Trial: 8215477
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of mitomycin C combined with PJ-203
Trial: 3441275
Drug: Scopolamine (0.25-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.25-0.75 mg i.m.)
Trial: 3441275
Drug: Scopolamine (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.50 and 0.75 mg i.m.)
Trial: 3441275
Drug: Scopolamine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.75 mg i.m.)
Trial: 3441275
Drug: Scopolamine (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.50 mg i.m.)
Trial: 20479485
Drug: Glucose-only beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-only beverage (G)
Trial: 18533979
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants with a coil spring
Trial: 18533979
Drug: Nonloaded implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonloaded implants with an annealed coil spring
Trial: 12756602
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) administered to 91 patients in the AG group
Trial: 1845926
Drug: Propranolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (beta 1/beta 2-antagonist)
Trial: 1845926
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-antagonist)
Trial: 31883703
Drug: Gantenerumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab (300 mg SC injection) at 5 seconds
Trial: 31883703
Drug: Gantenerumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab (300 mg SC injection) at 15 seconds
Trial: 31883703
Drug: Placebo (SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (SC injection into abdomen)
Trial: 31883703
Drug: Placebo (SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (SC injection into thigh)
Trial: 31883703
Drug: Gantenerumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gantenerumab (300 mg SC injection)
Trial: 23535882
Drug: SpineCor brace
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SpineCor brace treatment
Trial: 19767804
Drug: Isotonic sports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sports drink containing caffeine (6.4 g carbohydrate and 16 mg caffeine per 100 mL)
Trial: 9092955
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 400 mg/day
Trial: 9092955
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 600 mg/day
Trial: 9092955
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 800 mg/day
Trial: 8244132
Drug: Heater probe
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heater probe treatment
Trial: 3533562
Drug: bufuralol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bufuralol (60 mg)
Trial: 3533562
Drug: propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (160 mg)
Trial: 3533562
Drug: bufuralol (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bufuralol (30-60 mg bd)
Trial: 3533562
Drug: propranolol (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol (40-80 mg bd)
Trial: 31255349
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (HP) - 35% protein (1.34 g/kg/day)
Trial: 31255349
Drug: Standard-protein diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-protein diet (SP) - 18% protein (0.75 g/kg/day)
Trial: 20185740
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus weight loss (10 mg/day)
Trial: 18600034
Drug: Hydrocortisone (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (daily dose = 40 mg)
Trial: 10379635
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.1 U x kg‐body‐weight(‐1))
Trial: 10379635
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.1 U x kg‐body‐weight(‐1))
Trial: 8682965
Drug: Clindamycin 1%
RxNorm normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 1% topical solution
Trial: 6751705
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg xipamide daily for 7 days
Trial: 6751705
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg frusemide daily for 7 days
Trial: 29314376
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral D-amphetamine
Trial: 26031764
Drug: Finasteride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (1 mg/day)
Trial: 26031764
Drug: Combined medication
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medication (Finasteride + 5% Minoxidil)
Trial: 23057323
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose beta-conglycinin (4.6g in 8 test tablets daily)
Trial: 23057323
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose beta-conglycinin (2.3g in 4 test tablets daily)
Trial: 23057323
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 tablets containing no beta-conglycinin)
Trial: 21527026
Drug: Omalizumab (anti-IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (anti-IgE therapy)
Trial: 15774788
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2 weekly for 9 cycles)
Trial: 15774788
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 every 2 weeks for 4 cycles)
Trial: 12361192
Drug: ACEI +
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI + NAC (600 mg t.i.d.)
Trial: 8303575
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily fractionation schedules of 1.2 Gy/fraction, 1.4 Gy/fraction, and 1.6 Gy/fraction with an interfraction interval of four to six hours.
Trial: 30409443
Drug: MV-CHIK (5×10^4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MV-CHIK (5×10^4 or 5×10^5 50% tissue culture infectious dose)
Trial: 23646470
Drug: Yiqi Qushi
RxNorm normalized name: INTERLEUKIN 15 RECEPTOR .ALPHA. CHAIN (HUMAN SUSHI DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN FC FRAGMENT), DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiqi Qushi Recipe (YQR), one dose daily for eight weeks
Trial: 23646470
Drug: Pyridostigmine 60
RxNorm normalized name: pyRIDostigmine 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 60 mg, three times a day for eight weeks
Trial: 19736635
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of warfarin therapy
Trial: 19736635
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of warfarin therapy
Trial: 16354711
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (15-30 mg elemental zinc daily for 14 days)
Trial: 10709819
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 10 g over 20 minutes before sternotomy
Trial: 1928856
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl 3 micrograms.kg‐1.h‐1 (Group I)
Trial: 1928856
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl 1 microgram.kg‐1.h‐1 and enflurane 1.2 +/‐ 0.3 vol % (Group II)
Trial: 20455619
Drug: Quitline telephone
RxNorm normalized name: quinoline yellow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quitline telephone counseling for smoking cessation; details on dosage and duration not available.
Trial: 12440177
Drug: forced diuresis
RxNorm normalized name: benzalkonium chloride Topical Solution [Clean Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: forced diuresis with i.v. crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure was < 20 mmHg), and low dose dopamine
Trial: 12440177
Drug: intravenous crystalloid
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous crystalloid and matching placebos
Trial: 7573992
Drug: Computer-controlled infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer-controlled infusion of alfentanil (CCiA)
Trial: 7573992
Drug: Patient-controlled administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled administration of morphine (PCAM)
Trial: 7128131
Drug: Standardized dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized dose of ethinyl estradiol
Trial: 23837673
Drug: Allocation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allocation to treatment group
Trial: 21034687
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy + risperidone
Trial: 21034687
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy + placebo
Trial: 21034687
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy + placebo
Trial: 21034687
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (cognitive therapy + risperidone, cognitive therapy + placebo, supportive therapy + placebo)
Trial: 19158975
Drug: Paroxetine CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine CR (12.5-50 mg/day)
Trial: 14517708
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg daily for 6 days)
Trial: 11063909
Drug: Alpha-tocotrienyl acetate
RxNorm normalized name: alpha-Tocopherol acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-tocotrienyl acetate (250 mg/d)
Trial: 11063909
Drug: Gamma-tocotrienyl acetate
RxNorm normalized name: gamma-octalactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-tocotrienyl acetate (250 mg/d)
Trial: 11063909
Drug: Delta-tocotrienyl acetate
RxNorm normalized name: delta 9-tetrahydrocannabinol acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta-tocotrienyl acetate (250 mg/d)
Trial: 8817801
Drug: treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment A
Trial: 8817801
Drug: treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment B
Trial: 1433686
Drug: High-dose epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose epinephrine (HDE, 15 mg)
Trial: 1433686
Drug: Standard-dose epinephrine
RxNorm normalized name: epinephrine Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose epinephrine (SDE, 1 mg)
Trial: 1433686
Drug: High-dose norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose norepinephrine (NE, 11 mg)
Trial: 31698361
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin plus aspirin
Trial: 28832630
Drug: Budesonide/formoterol 160/4.5ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5ug twice daily (group II)
Trial: 28832630
Drug: Budesonide/formoterol 320/9ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 320/9ug twice daily (group III)
Trial: 28832630
Drug: Budesonide/formoterol 160/4.5ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160/4.5ug twice daily with tiotropium 18ug once daily (group IV)
Trial: 28832630
Drug: Tiotropium 18ug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18ug once daily (group I)
Trial: 25879343
Drug: Capecitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,000 mg/m² daily) and oxaliplatin (85 mg/m² IV)
Trial: 25879343
Drug: 5-FU (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (350 mg/m²) and leucovorin (20 mg/m²)
Trial: 23290547
Drug: Intracoronary enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary enalaprilat (50 μg)
Trial: 21088675
Drug: Lipid-heparin infusion
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-heparin infusion
Trial: 17868864
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment modalities for myeloproliferative HES
Trial: 17868864
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment modalities for idiopathic HES
Trial: 17868864
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment modalities for lymphocytic‐variant HES
Trial: 15521004
Drug: BILN 2061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILN 2061 500 mg twice daily for 2 days
Trial: 15521004
Drug: BILN 2061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILN 2061 200 mg twice daily for 2 days
Trial: 15521004
Drug: BILN 2061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILN 2061 25 mg twice daily for 2 days
Trial: 11161394
Drug: Amifostine (910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (910 mg/m² at day 1-3)
Trial: 9788689
Drug: Budesonide (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (topical steroid treatment)
Trial: 9788689
Drug: Levocabastine (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine (topical antihistamine)
Trial: 9788689
Drug: Polyclonal antibody
RxNorm normalized name: Polyclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyclonal antibody against SCF
Trial: 2791180
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg IV prochlorperazine
Trial: 321183
Drug: aspirin 3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 3.6 g daily
Trial: 31900997
Drug: Inhaled verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled verapamil (10 mg)
Trial: 31900997
Drug: Control (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (4 cc nebulized distilled water)
Trial: 29057836
Drug: Citrulline Malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline Malate (CM) 6 g
Trial: 26150574
Drug: Blood volume
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood volume expansion with albumin solution in 38°C (T38A)
Trial: 21726984
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 1g every 8 h (q8h) for 24 h
Trial: 21726984
Drug: 3‐h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐h infusion of 1 g q8h for 24 h
Trial: 21726984
Drug: 3‐h infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐h infusion of 2 g q8h for 24 h
Trial: 19292653
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (plain adhesive patch)
Trial: 12680181
Drug: Cyclophosphamide 500
RxNorm normalized name: cyclophosphamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 500 mg/m2 on days 1 and 2 plus epidoxorubicin 90 mg/m2 on day 1 every 3 weeks (group A)
Trial: 12680181
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2/cycle plus doxorubicin 50 mg/m2/cycle every 3 weeks (group B)